OBJECTIVE: • To investigate serum testosterone levels as a predictor for biochemical failure (BF) after radical retropubic prostatectomy (RRP). PATIENTS AND METHODS: • Prospective cohort study with 227 patients and a median follow-up of 7.7 years. • Total serum testosterone was measured at diagnosis. • Primary endpoint: 5-year BF-free survival defined as first PSA > 0.2 ng/mL. • Testosterone was tested as a predictor of BF as a dichotomized and continuous variable. RESULTS: • Median (range) age was 62 years (45-74), median PSA 9.9 ng/mL (0.4-96), and median testosterone was 14 nmol/L (2.2-40). • BF occurred for 57 patients (26%) within 5 years. • In multivariate analysis with age, PSA, and biopsy Gleason score, testosterone levels >11 nmol/L were an independent predictor for reduced risk of BF (hazard ratio, 0.53; 95% confidence interval, 0.31-0.90; P= 0.02). • When analyzed as a continuous variable, testosterone was not a statistically significant predictor of BF. CONCLUSION: • Low pretreatment serum testosterone levels correlate with a higher risk of BF, and testosterone may possess biological information about prostate cancer progression potential, which makes it an independent predictor of biochemical failure after RRP.
OBJECTIVE: • To investigate serum testosterone levels as a predictor for biochemical failure (BF) after radical retropubic prostatectomy (RRP). PATIENTS AND METHODS: • Prospective cohort study with 227 patients and a median follow-up of 7.7 years. • Total serum testosterone was measured at diagnosis. • Primary endpoint: 5-year BF-free survival defined as first PSA > 0.2 ng/mL. • Testosterone was tested as a predictor of BF as a dichotomized and continuous variable. RESULTS: • Median (range) age was 62 years (45-74), median PSA 9.9 ng/mL (0.4-96), and median testosterone was 14 nmol/L (2.2-40). • BF occurred for 57 patients (26%) within 5 years. • In multivariate analysis with age, PSA, and biopsy Gleason score, testosterone levels >11 nmol/L were an independent predictor for reduced risk of BF (hazard ratio, 0.53; 95% confidence interval, 0.31-0.90; P= 0.02). • When analyzed as a continuous variable, testosterone was not a statistically significant predictor of BF. CONCLUSION: • Low pretreatment serum testosterone levels correlate with a higher risk of BF, and testosterone may possess biological information about prostate cancer progression potential, which makes it an independent predictor of biochemical failure after RRP.
Authors: Andrea Salonia; Firas Abdollah; Umberto Capitanio; Andrea Gallina; Nazareno Suardi; Alberto Briganti; Giuseppe Zanni; Matteo Ferrari; Fabio Castiglione; Maria Chiara Clementi; Patrizio Rigatti; Francesco Montorsi Journal: World J Urol Date: 2012-03-24 Impact factor: 4.226
Authors: A Pichon; Y Neuzillet; H Botto; J-P Raynaud; C Radulescu; V Molinié; J-M Herve; T Lebret Journal: Prostate Cancer Prostatic Dis Date: 2015-10-06 Impact factor: 5.554
Authors: Alan L Kaplan; Jim C Hu; Abraham Morgentaler; John P Mulhall; Claude C Schulman; Francesco Montorsi Journal: Eur Urol Date: 2015-12-21 Impact factor: 20.096
Authors: Mieke Van Hemelrijck; Karl Michaelsson; William G Nelson; Norma Kanarek; Adrian Dobs; Elizabeth A Platz; Sabine Rohrmann Journal: Aging Male Date: 2013-05-14 Impact factor: 5.892